SYNI: AI 评分 46/100 — AI 分析 (4月 2026)

Synvista Therapeutics, Inc. is a biopharmaceutical company focused on developing diagnostic tests and drugs for diabetic patients at high risk for cardiovascular disease. Their pipeline includes ALT-2074 and Alagebrium chloride, both in Phase II clinical trials.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Synvista Therapeutics, Inc. is a biopharmaceutical company specializing in treatments for diabetic patients at risk of cardiovascular disease. Their pipeline features ALT-2074, a glutathione peroxidase mimetic, and Alagebrium chloride, an Advanced Glycation End-product Crosslink Breaker, both currently in Phase II clinical trials, positioning them in the competitive pharmaceuticals market.

SYNI是做什么的？

Synvista Therapeutics, Inc., formerly known as Alteon, Inc., was founded in 1986 and is headquartered in Parsippany, New Jersey. The company operates as a product-based biopharmaceutical entity, focusing on the development of diagnostic tests and drugs aimed at identifying and treating diabetic patients who are at high risk of developing cardiovascular disease. Synvista's product pipeline includes ALT-2074, a glutathione peroxidase mimetic currently in Phase II clinical trials for treating diabetic patients with the Hp2-2 genotype. Additionally, they are developing Alagebrium chloride, also in Phase II clinical trials, targeting diastolic heart failure and diabetic nephropathy. The company is also working on a diagnostic test designed to identify and treat diabetic patients at risk of cardiovascular disease. Synvista's strategic focus on diabetes-related cardiovascular complications positions it within a niche segment of the pharmaceutical industry, addressing a significant unmet medical need.

SYNI的投资论点是什么？

Synvista Therapeutics, Inc. presents a high-risk, high-reward investment profile due to its focus on developing treatments for diabetic patients at risk of cardiovascular disease. The company's pipeline, featuring ALT-2074 and Alagebrium chloride in Phase II trials, represents potential value drivers if clinical trials are successful. However, the company's small market capitalization and OTC listing introduce significant liquidity and regulatory risks. Successful completion of Phase II trials and subsequent partnerships or acquisitions could drive significant returns. The company's beta of -5.15 suggests an inverse correlation with the market, which may offer diversification benefits in certain market conditions.

SYNI在哪个行业运营？

Synvista Therapeutics operates within the medical pharmaceutical industry, a sector characterized by intense research and development, stringent regulatory oversight, and high capital requirements. The market for diabetes-related treatments is substantial, driven by the increasing prevalence of diabetes globally. Competition includes major pharmaceutical companies and smaller biotech firms focusing on innovative therapies. Synvista's focus on cardiovascular complications of diabetes positions it within a specialized niche, potentially offering a competitive advantage if its clinical trials are successful. The industry is also influenced by trends in personalized medicine and diagnostic testing, aligning with Synvista's development of a diagnostic test for cardiovascular risk in diabetic patients.

Medical - Pharmaceuticals

Healthcare

SYNI有哪些增长机遇？

Successful completion of Phase II clinical trials for ALT-2074: Positive results from the Phase II trials could lead to increased investor confidence and potential partnerships with larger pharmaceutical companies. The market for treatments targeting diabetic patients with the Hp2-2 genotype is significant, offering a substantial revenue opportunity if the drug proves effective. The timeline for Phase III trials and potential FDA approval could extend several years, but successful Phase II data would be a major catalyst.
Advancement of Alagebrium chloride through clinical trials: Alagebrium chloride targets diastolic heart failure and diabetic nephropathy, both significant complications of diabetes. Positive clinical trial results could open up a large market opportunity. The development timeline is lengthy, but successful trials would significantly increase the company's value. The market for heart failure and diabetic nephropathy treatments is substantial and growing.
Development and commercialization of a diagnostic test for cardiovascular risk in diabetic patients: A successful diagnostic test could provide a recurring revenue stream and differentiate Synvista from competitors. The market for diagnostic tests in diabetes is expanding, driven by the need for early detection and prevention of complications. The timeline for development and commercialization depends on regulatory approval and market adoption.
Strategic partnerships with larger pharmaceutical companies: Collaborations with established pharmaceutical companies could provide Synvista with funding, expertise, and access to larger markets. Partnerships could accelerate the development and commercialization of Synvista's products. The pharmaceutical industry is characterized by collaborations between smaller biotech firms and larger companies, offering potential opportunities for Synvista.
Expansion into new therapeutic areas within diabetes: Synvista could leverage its expertise in diabetes to develop treatments for other complications, such as retinopathy and neuropathy. Expanding the product pipeline would diversify the company's revenue streams and reduce its reliance on a single product. The market for diabetes treatments is broad and offers numerous opportunities for innovation.

Synvista Therapeutics focuses on developing diagnostic tests and drugs for diabetic patients at high risk for cardiovascular disease.
The company's lead product candidates, ALT-2074 and Alagebrium chloride, are both in Phase II clinical trials.
ALT-2074 is a glutathione peroxidase mimetic for the treatment of diabetic patients with Hp2-2.
Alagebrium chloride is an Advanced Glycation End-product Crosslink Breaker for the treatment of diastolic heart failure and diabetic nephropathy.
Synvista Therapeutics trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.

SYNI提供哪些产品和服务？

Develop diagnostic tests for diabetic patients at high risk for cardiovascular disease.
Develop drugs to treat diabetic patients at high risk for cardiovascular disease.
Focus on glutathione peroxidase mimetics for treating diabetic patients with Hp2-2.
Develop Advanced Glycation End-product Crosslink Breakers for treating diastolic heart failure and diabetic nephropathy.
Conduct Phase II clinical trials for ALT-2074.
Conduct Phase II clinical trials for Alagebrium chloride.

SYNI如何赚钱？

Develops and patents novel therapeutic compounds.
Conducts clinical trials to demonstrate safety and efficacy.
Seeks regulatory approval from the FDA.
Out-licenses or partners with larger pharmaceutical companies for commercialization.

Diabetic patients at high risk for cardiovascular disease.
Hospitals and clinics specializing in diabetes care.
Pharmaceutical companies seeking to expand their diabetes product portfolios.

Proprietary drug candidates with patent protection.
Specialized focus on cardiovascular complications of diabetes.
Clinical trial data demonstrating safety and efficacy.

什么因素可能推动SYNI股价上涨？

Upcoming: Release of Phase II clinical trial results for ALT-2074.
Upcoming: Announcement of potential partnerships with larger pharmaceutical companies.
Upcoming: Progress on the development of a diagnostic test for cardiovascular risk in diabetic patients.

SYNI的主要风险是什么？

Potential: Failure of clinical trials for ALT-2074 or Alagebrium chloride.
Ongoing: Competition from larger pharmaceutical companies with more resources.
Potential: Regulatory hurdles and delays in FDA approval.
Ongoing: Limited financial resources and reliance on external funding.
Ongoing: Risks associated with trading on the OTC market, including low liquidity and price volatility.

SYNI的核心优势是什么？

Focus on a specific niche within diabetes care (cardiovascular complications).
Proprietary drug candidates in Phase II clinical trials.
Potential for high returns if clinical trials are successful.

SYNI的劣势是什么？

Small market capitalization and limited financial resources.
Reliance on a small number of drug candidates.
OTC listing indicates higher risk and lower liquidity.

SYNI有哪些机遇？

Successful completion of Phase II trials could lead to partnerships with larger pharmaceutical companies.
Expansion into new therapeutic areas within diabetes.
Development and commercialization of a diagnostic test for cardiovascular risk in diabetic patients.

SYNI面临哪些威胁？

Failure of clinical trials.
Competition from larger pharmaceutical companies with more resources.
Regulatory hurdles and delays in FDA approval.

SYNI的竞争对手是谁？

Novo Nordisk — Major player in diabetes care with a broad portfolio of insulin and GLP-1 receptor agonists. — (NVO)
Eli Lilly and Company — Another major player in diabetes care with a diverse range of insulin and other diabetes medications. — (LLY)
Sanofi — Global pharmaceutical company with a significant presence in the diabetes market. — (SNY)

Key Metrics

MoonshotScore: 46/100

Company Profile

Headquarters: Parsippany, US
Employees: 9
Founded: 2000

AI Insight

AI analysis pending for SYNI

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Synvista Therapeutics, Inc. do?

Synvista Therapeutics, Inc. is a biopharmaceutical company focused on developing diagnostic tests and drugs for diabetic patients who are at high risk of developing cardiovascular disease. Their primary focus is on developing treatments for diabetic patients with the Hp2-2 genotype and for diastolic heart failure and diabetic nephropathy. The company's pipeline includes ALT-2074, a glutathione peroxidase mimetic, and Alagebrium chloride, an Advanced Glycation End-product Crosslink Breaker, both currently in Phase II clinical trials. Synvista also aims to develop a diagnostic test to identify diabetic patients at risk of cardiovascular disease, positioning them as a player in the personalized medicine approach to diabetes care.

What do analysts say about SYNI stock?

As of 2026-03-16, there is no available analyst coverage for Synvista Therapeutics, Inc. due to its OTC listing and small market capitalization. The company's valuation is highly dependent on the success of its clinical trials and its ability to secure partnerships or funding. Investors should conduct their own due diligence and carefully consider the risks associated with investing in a small, OTC-listed biopharmaceutical company. The lack of analyst coverage underscores the importance of independent research and a thorough understanding of the company's prospects and challenges.

What are the main risks for SYNI?

The main risks for Synvista Therapeutics, Inc. include the inherent risks associated with pharmaceutical development, such as the failure of clinical trials, regulatory hurdles, and competition from larger companies with more resources. The company's reliance on a small number of drug candidates increases its vulnerability to setbacks in clinical development. Additionally, its OTC listing exposes investors to risks associated with low liquidity, price volatility, and limited financial disclosure. Securing adequate funding to support ongoing clinical trials and operations is also a significant risk factor. Investors should carefully assess these risks before investing in Synvista Therapeutics, Inc.